APLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Apellis Pharmaceuticals Inc (APLS) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is being acquired by Biogen at a fixed price of $41 per share, leaving little room for further appreciation. Additionally, the lack of significant growth catalysts, coupled with the overbought technical indicators, suggests limited upside potential.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram of 0.694, indicating an uptrend. However, the RSI of 94.632 signals overbought conditions, suggesting limited short-term upside. The stock is trading near its resistance level of $40.866, with minimal price movement expected due to the acquisition.
Biogen's acquisition of Apellis for $41 per share in cash provides a clear exit strategy for current shareholders. Hedge funds have increased their buying activity by 132.99% over the last quarter.
The acquisition caps the stock's upside at $41 per share, leaving little room for further appreciation. Investigations by Halper Sadeh LLC regarding potential shareholder rights violations could create uncertainty.
In Q4 2025, revenue dropped by -5.94% YoY to $199.91M, while net income improved by 62.16% YoY to -$58.95M. EPS also increased by 62.07% YoY to -0.47, and gross margin rose to 85.13%, up 5.38% YoY. Despite some improvements, the company remains unprofitable.
Analysts have downgraded the stock to Neutral or Hold due to the acquisition by Biogen. The price target has been consistently set at $41, reflecting the acquisition price. There is no expectation of further competitive bidding or significant price appreciation.
